Verona Pharma Q2 2024 GAAP EPS $(0.11) Beats $(0.38) Estimate; Cash position $404.6M
Portfolio Pulse from Benzinga Newsdesk
Verona Pharma (NASDAQ:VRNA) reported Q2 2024 GAAP EPS of $(0.11), significantly beating the analyst consensus estimate of $(0.38). The company also reported a cash position of $404.6M.
August 08, 2024 | 6:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verona Pharma reported Q2 2024 GAAP EPS of $(0.11), beating the analyst estimate of $(0.38) by 71.05%. The company also has a strong cash position of $404.6M.
The significant beat on EPS estimates and strong cash position are positive indicators for Verona Pharma, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100